Durham company sees promise in clinical trials for leukemia treatment

A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future. Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment. PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news